Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Fluoxetine capsulesand fluoxetine oral solutionis a selective serotonin reuptake inhibitor for oral administration.

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Domperidone Maleate Manufacturers in India Suppliers Domperidone Maleate Exporters Distributors Domperidone Maleate api active pharmaceuticals ingredients Domperidone Maleate manufacturers Side Effects bulk drugs raw material Domperidone Maleate companies Side Effects Importers Domperidone Maleate Domperidone Maleate Exporters Domperidone Maleate exporters FDA Domperidone Maleate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Domperidone Maleate manufacturing pharmaceutical drugs pharmaceutical intermediates Domperidone Maleate pharmaceutical chemicals pharmaceutical raw materials Domperidone Maleate active pharmaceutical ingredients Domperidone Maleate committee active pharmaceutical ingredients manufacturer Domperidone Maleate Active Pharmaceutical Ingredients manufacturer Domperidone Maleate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Domperidone Maleate, Domperidone Maleate manufacturer India, Domperidone Maleate product, Domperidone Maleate products, Api preparation, Certificate of Analysis API manufacturer product, Domperidone Maleate anti ulcer product, Certificate of Origin COA Domperidone Maleate COS Domperidone Maleate, pharmaceutical generic, pharmaceutical drug, medical, Domperidone Maleate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Domperidone Maleate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Domperidone Maleate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Domperidone Maleate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Domperidone Maleate ingredients, api, HIV Domperidone Maleate, tablets, capsules, syrup & protein Domperidone Maleate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Domperidone Maleate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Domperidone Maleate WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

purified water,






















































 

 

HOME >> Pharmaceuticals API List 1 >> Domperidone Maleate



Domperidone Maleate pdf api
CAS number 99497-03-7

Structure Formula :

Identification

Synonyms 5-Chloro-1-[1-[3-(2-oxo-1,3-dihydrobenzoimidazol-1-yl)propyl]-4-piperidyl]-1,3-dihydrobenzoimidazol-2-one maleate
Molecular Structure Domperidone maleate, 5-Chloro-1-[1-[3-(2-oxo-1,3-dihydrobenzoimidazol-1-yl)propyl]-4-piperidyl]-1,3-dihydrobenzoimidazol-2-one maleate,

CAS Registry Number 99497-03-7
Molecular Formula C22H24ClN5O2.C4H4O4
Molecular Weight 541.99
Appearance: White or almost white powder
Use: Digestive system drugs
Standard: BP/USP/CP
Package: 25KG/Drum

Description

Domperidone is a peripheral dopamine antagonist structurally related to the butyrophenones with antiemetic and gastroprokinetic properties.

Domperidone effectively increases esophageal peristalsis and lower esophageal sphincter pressure (LESP), increases gastric motility and peristalsis, enhances gastroduodenal coordination and consequently facilitates gastric emptying and decreases small bowel transit time.

The mechanism of action of domperidone is related to its peripheral dopamine receptor blocking properties. Emesis induced by apomorphine, hydergine, morphine or levodopa through stimulation of the chemoreceptor trigger zone (situated outside the blood-brain barrier) can be blocked by domperidone. There is indirect evidence that emesis is also inhibited at the gastric level, since domperidone also inhibits emesis induced by oral levodopa, and local gastric wall concentrations following oral domperidone are much greater than those of the plasma and other organs. Domperidone does not readily cross the blood-brain barrier and therefore is not expected to have central effects.

Domperidone elevates serum prolactin levels but has no effect on circulating aldosterone levels.

Warnings

In Clinical States: Dopamine receptor blocking agents elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of dopamine receptor blocking agents. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis. The available evidence is considered too limited to be conclusive at this time.

Precautions

In the event that the patient develops galactorrhea and/or gynecomastia, withdrawal of the drug will result in alleviation of these symptoms.

Drug Interactions

The concomitant administration of anticholinergic drugs may compromise the beneficial effects of domperidone.
Since domperidone enhances gastric and small intestinal motility, it may accelerate absorption of drugs from the small bowel while slowing absorption of drugs taken up from the stomach, particularly those with sustained-release or enteric-coated formulations.

Care should be exercised when domperidone is administered in combination with MAO inhibitors.

The concomitant administration of domperidone maleate with antacids or H2-receptor blockers does not decrease the absorption of domperidone.

Dosage And Administration

Upper Gastrointestinal Motility Disorders: The usual dosage in adults is 10 mg orally 3 to 4 times a day, 15 to 30 minutes before meals and at bedtime if required. In severe or resistant cases the dose may be increased to a maximum of 20 mg 3 to 4 times a day.

Nausea and Vomiting Associated with Dopamine Agonist Antiparkinsonian Agents: The usual dosage in adults is 20 mg orally 3 to 4 times a day. Higher doses may be required to achieve symptom control while titration of the antiparkinsonian medication is occurring.
 

 
PDF DOWNLOAD WORD DOCUMENT
 

Taj pharmaceuticals API Logo

Domperidone Maleate

More Api at Taj Pharmaceuticals Ltd.

Alfuzosin

Oseltamivir Phosphate

 Amlodipine Besylate

Aripiprazole

Atorvastatin Calcium

Candesartan Cilaxetil

Cefdinir

Cetirizine Dihydrochloride

Ciprofloxacin HCl

Dextromethorphan Base

Diltiazem HCl

Domperidone Base

Domperidone Maleate

Doxazosin Mesylate

 Duloxetine HCl

Dutasteride

Enalapril Maleate

Esomeprazole Magnesium

Famotidine

Fexofenadine HCl

Fluconazole

Fluoxetine HCl

Galantamine HBr

Ibuprofen

Caffeine

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.